Clinical trial
A Phase 2a Open-label Study of the Oral Farnesoid X Receptor (FXR) Modulator EYP001a to Assess Its Safety and Anti-viral Effect in Chronic Hepatitis B (CHB) Patients in Combination With Pegylated Interferon alpha2a (Peg-IFN) Alone and With Entecavir (ETV)
NCT04365933 is registered in ClinicalTrials.gov with Enyo Pharma as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 2a Open-label Study of the Oral Farnesoid X Receptor (FXR) Modulator EYP001a to Assess Its Safety and Anti-viral Effect in Chronic Hepatitis B (CHB) Patients in Combination With Pegylated Interferon alpha2a (Peg-IFN) Alone and With Entecavir (ETV)
- Lead sponsor
- Enyo Pharma
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- May 25, 2020
- Completion date
- November 29, 2021
- Enrollment
- 20 (actual)
- Sites
- 6
Conditions
As the registry lists them; a condition with its own page is linked.